Immuno-oncology
Conference Coverage
High pCR rate in HPV+ HNSCC with nivolumab/SBRT
ATLANTA – Nine of 10 patients in a phase 1/1b trial had pathologic complete responses to neoadjuvant nivolumab and radiation.
Conference Coverage
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...
Feature
ICYMI: NIH renames, streamlines gene therapy committee
The Recombinant DNA Advisory Committee will now be known as the Novel and Exceptional Technology and Research Advisory Committee.
Opinion
Lessons from KEYNOTE-158 and the role of R-CHOP
Dr. Alan P. Lyss breaks down the clinical relevance of two recent studies in advanced cervical cancer and diffuse large B-cell lymphoma.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
From the Journals
Immunotherapy overtaking breast cancer treatment landscape
Review authors suggest combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding...